These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 12845660)
1. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660 [TBL] [Abstract][Full Text] [Related]
2. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772 [TBL] [Abstract][Full Text] [Related]
3. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Diamandis EP; Borgoño CA; Scorilas A; Harbeck N; Dorn J; Schmitt M Clin Biochem; 2004 Sep; 37(9):823-9. PubMed ID: 15329323 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Skírnisdóttir I; Seidal T Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012 [TBL] [Abstract][Full Text] [Related]
6. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Diamandis EP; Borgoño CA; Scorilas A; Yousef GM; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M Tumour Biol; 2003; 24(6):299-309. PubMed ID: 15004490 [TBL] [Abstract][Full Text] [Related]
7. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091 [TBL] [Abstract][Full Text] [Related]
8. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273 [TBL] [Abstract][Full Text] [Related]
9. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. McIntosh MW; Liu Y; Drescher C; Urban N; Diamandis EP Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4422-8. PubMed ID: 17671125 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815 [TBL] [Abstract][Full Text] [Related]
11. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797 [TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288 [TBL] [Abstract][Full Text] [Related]
13. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443 [TBL] [Abstract][Full Text] [Related]
14. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453 [TBL] [Abstract][Full Text] [Related]
15. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Shan SJ; Scorilas A; Katsaros D; Rigault de la Longrais I; Massobrio M; Diamandis EP Clin Chem; 2006 Oct; 52(10):1879-86. PubMed ID: 16916986 [TBL] [Abstract][Full Text] [Related]
16. DEF6 expression in ovarian carcinoma correlates with poor patient survival. Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer. Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194 [TBL] [Abstract][Full Text] [Related]
18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549 [TBL] [Abstract][Full Text] [Related]
19. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448 [TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]